Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
Exercise Relates to Remaining Tranche 1 Warrants
The exercise period of the tranche 1 and tranche 2 warrants was tied to the clinical success of the Company’s CTP-543 THRIVE-AA1 and THRIVE-AA2 Phase 3 trials for alopecia areata. Concert reported positive topline results from the THRIVE-AA1 and THRIVE-AA2 trials in
About Concert
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including, among others, statements about our expectations regarding the development of CTP-543, the planned timing for filing an NDA for CTP-543 and the sufficiency of our cash, cash equivalents and investments to fund our operations, and any other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results, including safety profiles, from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for the timing of the submission of an NDA, the availability of regulatory approvals, the availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements, expectations with respect to the protection of our intellectual property afforded by our patents and other factors discussed in the “Risk Factors” section of our most recent Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005159/en/
(781) 674-5284
ir@concertpharma.com
The Yates Network
(914) 204-6412
kathryn@theyatesnetwork.com
Source: